To hear about similar clinical trials, please enter your email below
Trial Title:
Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion
NCT ID:
NCT05596578
Condition:
Lung Cancer
Lymph Node Metastasis
Conditions: Official terms:
Lymphatic Metastasis
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
Background: Lung cancer is the leading cause of cancer related death worldwide. More than
80% of all lung tumors are Non-Small Cell Lung Cancers (NSCLC). Lymph node staging has a
prognostic value and is crucial to establish the optimal treatment strategy in individual
patients. It remains unknown whether dissecting the intrapulmonary lymph nodes (stations
13 and 14) is necessary for accurate staging and prognostication. Although suggested by
several guidelines, these peripheral lymph nodes are not routinely examined in clinical
routine for several reasons. Moreover, the prognostic significance of the visceral
pleural invasion is controversial. Some studies showed a negative impact on OS and DFS in
patients with histologic proved visceral pleura invasion.
The mechanism to explain this negative effect is not fully understood. Given that the
visceral pleura is very rich in lymphatic vessels, with an intercommunicating "network"
arranged over the lung surface and penetrating into the lung parenchyma to join the
bronchial lymph vessels with drainage to the various hilar nodes, we assume that the
worse OS and DFS observed in these patients could be explained with the presence of
metastatic lymph nodes (Station 13-14) that are not routinely examined. Methods: This is
a prospective, multicenter study based on ad-hoc created prospectively database. The
incidence of N1 lymph node metastasis overall and the incidence of metastasis to the
different lymph node stations (Hilar 10/11, Lobar 12, Sublobar 13/14) will be calculated
by dividing the number of the respective events by the patient years separately. To
investigate the association between visceral pleural invasion and the presence of
metastatic lymph nodes univariate and multivariate logistic regression models will be
fitted to the data.
Discussion: The primary outcome is to investigate the incidence of N1 metastases
(especially stations 12,13,14) and his relationship with visceral pleural invasion. The
secondary outcomes is to evaluate the impact of N1 metastases and/or visceral pleural
invasion on long-term outcomes (OS and DFS) along with incidence and pattern of
recurrence. DFS is defined as the time of surgical intervention to tumor recurrence or
death, and OS is defined as the time of surgical intervention to death
Criteria for eligibility:
Study pop:
Patients recorded prospectively in the database from January 2023 to December 2024 that
meet the inclusion and exclusion criteria
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Anatomical resection for NSCLC <3 cm (lobectomy, bilobectomy, segmentectomy)
- Samples from the intrapulmonary stations 12, 13, and 14 lymph nodes
- Resection of lymphnodes station 10 and 11 during hilar separation.
- R0 resection
Exclusion Criteria:
- Prior or synchronous lung cancer
- pN2
- Pneumonectomy
- R1/R2 resection
- M1
- Neoadjuvant treatment
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Kantonsspital Luzern
Address:
City:
Lucerne
Zip:
6000
Country:
Switzerland
Status:
Recruiting
Contact:
Last name:
Fabrizio Minervini, MD, PhD
Phone:
0764553460
Email:
fabriziominervini@hotmail.com
Start date:
January 1, 2023
Completion date:
December 31, 2029
Lead sponsor:
Agency:
Luzerner Kantonsspital
Agency class:
Other
Source:
Luzerner Kantonsspital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05596578